Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Metformin Stories

Diabetes Drug Metformin Works Differently Than Previously Believed
2013-01-07 04:40:00

redOrbit Staff & Wire Reports - Your Universe Online Metformin, the drug most frequently prescribed by doctors to treat Type 2 Diabetes, works differently than previously believed -- a discovery which could lead to new treatments that have fewer side effects. Lead researcher Dr. Morris J. Birnbaum, a professor at the University of Pennsylvania's Institute for Diabetes, Obesity, and Metabolism (IDOM), and an international team of scientists have discovered that, in mice, metformin...

2012-12-12 08:28:16

RARITAN, N.J., Dec. 12, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for a fixed-dose therapy combining canagliflozin and immediate release metformin to treat patients with type 2 diabetes. Canagliflozin is an investigational, oral medication for the treatment of adult patients with type 2 diabetes. The kidneys of people with type 2 diabetes...

Diabetes Drug Helps Treat Cancer
2012-12-03 20:08:50

Lee Rannals for redOrbit.com — Your Universe Online A common diabetes medication could help in preventing or treating ovarian cancer, according to research published in the journal CANCER. The study found that ovarian cancer patients who took the drug tended to live longer than those patients who did not take it. Previous research showed that metformin, which originated from the French Lilac plant, might have anticancer properties. In the new study, the researchers analyzed...

2012-12-03 16:24:22

NEWARK, Calif., Dec. 3, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it will be presenting at the Oppenheimer 23rd Annual Healthcare Conference at the Waldorf Astoria Hotel in New York City. The presentation at the Oppenheimer conference is scheduled for 10:35 am EST (7:35 am PST) on Wednesday, December 12, 2012. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording...

2012-11-19 16:29:51

MENLO PARK, Calif., Nov. 19, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the Piper Jaffray 24(th) Annual Healthcare Conference at the Palace Hotel in New York City. The presentation at the Piper conference is scheduled for 10:00 am EST (7:00 am PST) on Tuesday, November 27, 2012. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the...

2012-11-09 04:20:56

BARCELONA, Spain, Nov. 9, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced that its investigational medicine canagliflozin substantially lowered blood glucose levels compared to placebo when used as add-on therapy in patients with type 2 diabetes who are inadequately controlled with the antihyperglycemic medications metformin and pioglitazone. These results were presented at the 4th World Congress on Controversies to Consensus in Diabetes, Obesity, and...

2012-11-06 08:27:51

MENLO PARK, Calif., Nov. 6, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the Lazard Capital Markets 9(th) Annual Healthcare Conference in New York City. The presentation at the Lazard conference is scheduled for 10:30 am EST (7:30 am PST) on Wednesday, November 14, 2012. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the...

2012-10-29 07:25:45

MENLO PARK, Calif., Oct. 29, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release third quarter fiscal year 2012 financial results after the market closes on Monday, November 5, 2012. The Company will host a conference call beginning at 5:00 pm Eastern time, 2:00 pm California time to discuss its results. Participants can access the call by dialing 877-317-6789 (United States) or 412-317-6789 (international). The conference call will also be available via a...

2012-10-26 11:23:50

GLEN ALLEN, Va., Oct. 26, 2012 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: STSI) announced today that the press release issued 10/24/2012, titled "Star Scientific Announces Successful First Look at the "Flint" CRP Human Study and Provides Updated Report on ASAP Human Thyroid Study", incorrectly stated the interim results of the "Flint" CRP study. In the release, the Company reported: "After one month of supplementation, CRP levels dropped in 26% of the subjects with diabetes, compared...

2012-10-16 04:01:55

The primary objective of this 22 week study is to investigate the change in glycosylated hemoglobin (HbA1c) after receiving the new drug, as compared to those receiving a placebo. Birmingham, AL (PRWEB) October 15, 2012 In recent years, the number of patients with type 2 diabetes has continuously been increasing worldwide. According to the information published in 2009 by the International Diabetes Federation (IDF), the number of patients with diabetes was estimated to be 285 million...